RBV

1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide

RBV as a free ligand exists in 3 entries. Examples include: 3SFU 5AXD 4PB1

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

Name1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide
Identifiers1-[(2R,3R,4S,5R)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
FormulaC8 H12 N4 O5
Molecular Weight244.21
TypeNON-POLYMER
Isomeric SMILESNC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
InChIInChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
InChIKeyIWUCXVSUMQZMFG-AFCXAGJDSA-N

Chemical Details

Formal Charge0
Atom Count29
Chiral Atom Count4
Chiral AtomsC1', C2', C3', C4'
Bond Count30
Aromatic Bond Count5
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00811 Different stereochemistry
NameRibavirin
Groupsapproved
DescriptionA nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]
Synonyms
  • 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
  • 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
  • RBV
  • Ribavirin
  • Ribavirina
SaltsRibavirin monophosphate
Brand Names
  • Copegus
  • Ibavyr
  • Moderiba
  • Pegasys Rbv
  • Pegetron
Affected OrganismHepatitis C virus, RSV and other RNA/DNA viruses
IndicationFor the treatment of chronic hepatitis C and for respiratory syncytial virus (RSV).
PharmacologyRibavirin is an anti-viral drug active against a number of DNA and RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to it's resemblence to building blocks of the RNA molecules. The oral form is used in the treatment of hepatitis C, in combination with interferon drugs. The aerosol form is used to treat respiratory syncytial virus-related diseases in children. The primary serious adverse effect of ribavirin is hemolytic anemia, which may worsen preexisting cardiac disease.
Mechanism of actionRibavirin is readily phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral) and can be incorporated into RNA in RNA viral species.. Guanylyltranserase inhibition stops the capping of mRNA. These diverse effects result in a marked reduction of intracellular guanosine triphosphate (GTP) pools and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity.
Route of administration
  • Oral
  • Oral; Subcutaneous
  • Respiratory (inhalation)
Categories
  • Anti-Infective Agents
  • Antiinfectives for Systemic Use
  • Antimetabolites
  • Antiviral Agents
  • Antivirals for Systemic Use
ATC-CodeJ05AB04
AHFS-Code08:18.32
CAS number36791-04-5
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682